Beijing Biostar Pharmaceuticals Co., Ltd. (02563.HK)

Beijing Biostar Pharmaceuticals Co. Ltd. engages in the provision of treatment for tumor. The company is headquartered in Beijing, Beijing and currently employs 147 full-time employees. The company went IPO on 2024-10-31. The firm's products and pipeline mainly include Utidelone Injection, Utidelone Capsule, Utidelone Nanoformulation, Utidelone Antibody Drug Conjugate (ADC), BG22, BG18 and BG44. The firm's products are principally used for the treatment of relapsed or metastatic breast cancer, neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-breast cancer neoadjuvant, advanced non-small cell lung cancer (NSCLC), solid tumors, breast cancer brain metastasis, lung cancer brain metastasis and other brain tumor indications. The firm mainly conducts its businesses in the domestic market.